Newly Approved Medication Update
Golden L. Peters, Pharm.D., BCPS

In 2019, 48 new medications were approved by the FDA and so far in 2020 there have been 6 newly approved medications. The presentation will highlight selected new medications to review each medications indication, specific mechanism of action, dosing information, contraindications, precautions, adverse drug reactions, drug interactions, special administration techniques (when needed), and potential place in current therapy. The presentation will also highlight any special patient instruction or monitoring parameters for providers to take into account when prescribing these new medications. (e.g. injection techniques, priming requirements) New generic medications will be presented, along with any updated FDA recommendations or recent labeling changes to mainstream medications.

The Highs & Lows of HTN Medication Management
Brittany Shoults, AGPCNP-C

Coming soon

Interdisciplinary Approach to Headache Management
Eve Holzemer, DNP, ANP-BC

This session will have a brief review of the pathophysiology of Migraine Headaches, common triggers for Migraine headache and enable participants to differentiate the types of headache. The main focus of the presentation is to describe traditional and non-traditional treatments for Migraine headache.
Primary Care Management of Anxiety and Depression Medication.
Debbie Lynn Kelly, MSN, RN, PMHNP-BC

This interactive session will discuss medication management of anxiety and depression in primary care. The discussion will include a brief review of the prevalence of both depression and anxiety, screening tools that can be used when prescribing and when to refer to psychiatry as well as small group discussion/case studies.

Update on Pharmacotherapy for Obesity
Susan R. Reeds, MD, FACP

Discuss indications/rationale for use of medications in the treatment of obesity. Review currently available anti-obesity medications and their appropriate use. This will include mechanism of action of medications, choice of medication in specific circumstances, discussion of off-label use of medications not FDA-approved for treating obesity.